Heska price target raised to $240 from $220 at Piper Sandler » 04:5605/1005/10/21
Piper Sandler analyst…
Piper Sandler analyst Steven Mah raised the firm's price target on Heska to $240 from $220 and keeps an Overweight rating on the shares following the Q1 results. The analyst believes Heska is well positioned for long-term growth with macro pet trends are expected to be durable.
Heska price target raised to $240 from $230 at Alliance Global Partners » 11:3605/0705/07/21
Alliance Global Partners…
Alliance Global Partners analyst Ben Haynor raised the firm's price target on Heska to $240 from $230 and keeps a Buy rating on the shares after the company reported total revenue and results on each revenue line that topped his expectations. While Heska is clearly benefiting from a strong veterinary diagnostics market, there are signs that the company continues to perform better than the industry, according to Haynor, who has "significantly" increased his estimates.
Heska reports Q1 non-GAAP EPS 59c, consensus (41c) » 08:2805/0605/06/21
Reports Q1 revenue…
Reports Q1 revenue $60.5M, consensus $52.45M. "I'm pleased to report a great start to the year," commented CEO Kevin Wilson. "In our North America segment, POC Lab Consumables sales grew 23.9% from expanding utilization, good market share, expanding menu, and strong end-user demand. Imaging grew 91.3%, benefiting from the work we did last year to reorganize and expand our sales force into a unified, customer-location structure. Our International segment delivered a very solid start to the year in nearly all geographies, with great momentum in POC Lab Consumables and adoption of our subscriptions model in select European markets. (...) Also in Q1, we successfully raised substantial growth capital to go faster in launching new analyzer platforms, new test menus, new diagnostics services, and new international initiatives. While we are mindful of our competition and of the universal tendency for things to be difficult while going faster, the strong beginning to 2021 and the favorable setup for the rest of the year is highly encouraging. Our underlying markets are well positioned for the current macro-economic environment".
|Over a month ago|
new option listings on March 24th » 08:3003/2403/24/21
ACET, ALUS, ANIX, ATHA, BBAX, BBJP, BWEN, CBLI, EQ, FBIO, FDMT, FLOT, HSKA, IMAB, JPST, LIZI, OLMA, PLRX, RAAS, RPTX, SCR, SLGG, TFII, ZNTL
New option listings for…
New option listings for March 24th include Adicet Bio (ACET), Alussa Energy Acquisition Corp (Class A Stock) (ALUS), Anixa Biosciences Inc (ANIX), Athira Pharma Inc (ATHA), JPMorgan BetaBuilders Developed Asiaex Japan ETF (BBAX), JPMorgan BetaBuilders International Equity (BBIN), JPMorgan BetaBuilders Japan ETF (BBJP), Broadwind Energy (BWEN), Cleveland BioLabs (CBLI), Global X (COPX), Global X SuperDividend US (DIV), Equillium Inc (EQ), Fortress Biotech (FBIO), 4D Molecular Therapeutics Inc (FDMT), iShares Floating Rate (FLOT), Heska (HSKA), I MAB (ADS) (IMAB), Jpmorgan Equity Premium Income ETF (JEPI), JPMorgan Ultra-Short Income ETF (JPST), LIZHI Inc (ADS) (LIZI), Olema Pharmaceuticals Inc (OLMA), Pliant Therapeutics Inc (PLRX), Cloopen Group Holding Limited (Class A ADS) (RAAS), First Trust NASDAQ Rising Dividend Achievers (RDVY), Repare Therapeutics Inc (RPTX), Score Media and Gaming Inc (Class A Stock) (SCR), Super League Gaming Inc (SLGG), TFI International Inc (TFII), and Zentalis Pharmaceuticals Inc (ZNTL).
Heska 941K share Secondary priced at $186.00 » 06:2603/0303/03/21
The deal size was…
The deal size was increased to $175M in common stock from $150M in common stock. JPMorgan and Piper Sandler acted as joint book running managers for the offering.
Heska files automatic mixed securities shelf 16:1803/0103/01/21
Heska announces $150M common stock offering » 16:1003/0103/01/21
Heska Corporation announced that it has commenced an underwritten public offering of $150M of shares of its common stock. Heska intends to use the net proceeds from the offering for general corporate purposes, including working capital, further development and potential commercialization of current and future product initiatives, collaborations, and capital expenditures. Heska may also use a portion of the net proceeds of this offering to fund possible investments in or acquisitions of complementary businesses, products or technologies, or to repay indebtedness. However, it has no agreements or commitments to do so. J.P. Morgan and Piper Sandler are acting as joint book-running managers for the offering.
BofA to hold a virtual summit » 10:2302/2502/25/21
HSKA, ZTS, KIN, IDXX, PAHC, ELAN
Animal Health Virtual…
Animal Health Virtual Summit 2021 to be held on February 25.
Heska price target raised to $230 from $167.50 at Alliance Global Partners » 08:2902/2402/24/21
Alliance Global Partners…
Alliance Global Partners analyst Ben Haynor raised the firm's price target on Heska to $230 from $167.50 and reiterates a Buy rating on the shares following the company's Q4 beat. The underlying metrics of Heska's business are solid and management is being conservative in their guidance, Haynor tells investors in a research note.
Heska price target raised to $220 from $157 at Piper Sandler » 16:2302/2302/23/21
Piper Sandler analyst…
Piper Sandler analyst Steven Mah raised the firm's price target on Heska to $220 from $157 and keeps an Overweight rating on the shares following the company's Q4 results. Heska's business model has shown "strong resiliency" despite COVID-19 headwinds, Mah tells investors in a research note. The analyst believes the company is positioned for long-term sustainable growth with upcoming product launches, entry into cytology increasing international traction, plus ongoing strength in pet ownership trends extending into 2021.